All In Biotech

Drug Trial Radar · NCT00732524

Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA

Combination of Sulfonylureas and Insulin Glargine as Safety Net Outpatient Therapy for Unstable Diabetes and Impending Diabetic Ketoacidosis (DKA)

Last checked: Nov 20, 2026Latest source record: Aug 12, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Sep 2004

Primary completion

Apr 2006

Study completion Apr 2006

Sponsor

Lead sponsor
Cook County HealthGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Aug 12, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare two simple and safe emergency department discharge therapy for Type 2 Diabetes patients with severe hyperglycemia and with no indications for inpatient admission.

Conditions

  • Type 2 Diabetes

Interventions

  • GlipizideDrug

    Glipizide XL 10 mg once daily 30 mins before breakfast

  • Glipizide and GlargineDrug

    Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary outcome was the patients' ability to avoid repeat ED visits or hospitalization in either of the discharge regimens.Time frame: 2 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • John H Stroger Hospital Of Cook County

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.